ALNY Alnylam Pharmaceuticals Inc.

-1.15  -1%
Previous Close 118.70
Open 119.64
Price To book 9.60
Market Cap 10783257526
Shares 91,733,369
Volume 1,022,417
Short Ratio 2.96
Av. Daily Volume 1,470,680

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial initiation announced September 26, 2017 with initial data due 2018.
ALN-CC5 (cemdisiran)
Atypical hemolytic-uremic syndrome (aHUS)
Phase 2 trial suspended dosing due to fatal thrombotic event - noted September 7, 2017.
Hemophilia A and B
Phase 3 trial to commence in 2017. Data due by end of 2019.
Phase 3 trial to be initiated late 2017 with interim analysis data available in mid-2018.
Acute hepatic porphyrias
Phase 1/2 trial initiated July 2016. Ongoing as of February 2017.
Chronic hepatitis B virus (HBV)
Phase 1/2 initiated March 2016. Initial data released September 2016.
Primary Hyperoxaluria Type 1 (PH1)
Phase 3 top-line data released September 20, 2017 - all endpoints met. NDA filing due by end of 2017.
Patisiran APOLLO
Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR
Phase 3 trial discontinued October 2016.
ATTR in patients with familial amyloidotic cardiomyopathy (FAC)
Phase 1/2 initial data presented at ASH 2016.
Paroxysmal nocturnal hemoglobinuria (PNH)
Phase 3 program initiation announced July 7, 2017 with initial data due mid-late 2019. Dosing has yet to be initiated - noted September 7, 2017 that Fitusiran program suspended dosing due to fatal thrombotic event.
Fitusiran (ATLAS)
Development plan to be confirmed following APOLLO data release in mid 2017.
ATTR amyloidosis

Latest News

  1. Alnylam to partner with Scangos-led biotech on infectious disease drugs
  2. UPDATE 1-Alnylam, Vir partner on RNAi-based hep B treatment
  3. Alnylam, Vir partner on RNAi-based drugs for infectious diseases
  4. Alnylam's stock set to rally after exclusive license deal with Vir Biotechnology
  5. Alnylam and Vir Form Strategic Alliance to Advance RNAi Therapeutics for Infectious Diseases
  6. See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.
  7. Here's Why Alnylam Pharmaceuticals Rallied 32.7% in September
  8. Analysts Act on Health Care Stocks
  9. Why Biotech and Tech Will Push Stocks Higher In 4Q
  10. Alnylam Initiates Phase 2 Clinical Study of Cemdisiran (ALN-CC5) in Patients with Atypical Hemolytic-Uremic Syndrome (aHUS)
  11. Gene Therapy: A Big Week for Many Names
  12. Alnylam Continues Leadership in RNAi Technologies and Delivery with New Pre-Clinical Data Presented on "Enhanced Stabilization Chemistry Plus" (ESC+) GalNAc-siRNA Conjugate Platform at 13th Annual Meeting of the Oligonucleotide Therapeutics Society
  13. Edited Transcript of ALNY earnings conference call or presentation 9-Aug-17 8:30pm GMT
  14. 3 Biotech Stocks That Skyrocketed This Week: Can They Go Higher?
  15. [$$] Alnylam's New Medicine To Enter Pricing Debate
  16. Alnylam Is Entering 'New Chapter,' But Ionis Still Has A Chance
  17. Alnylam Pharmaceuticals: Bet or Fold?
  18. Alnylam Pharmaceuticals CEO: Trial results open up the do...